A Detouring Experience Not Recommended: Lessons Learned from PF00299804

被引：0

作者：

Li, Molly ^{[1
,2
]}

Mok, Kevin ^{[3
]}

Mok, Tony ^{[1
,2
,4
]}

机构：

[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[3] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[4] Chinese Univ Hong Kong, Dept Clin Oncol, Shatin, 30-32 Ngan Shing St, Hong Kong, Peoples R China

来源：

CANCER RESEARCH | 2022年 / 82卷 / 20期

关键词：

CELL LUNG-CANCER; DOUBLE-BLIND; DACOMITINIB; EGFR; OSIMERTINIB; INHIBITOR; MUTATIONS;

D O I：

10.1158/0008-5472.CAN-22-2638

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with mutant EGFR positive non-small cell lung cancer (NSCLC) benefit from tyrosine kinase inhibitor (TKI) treatment. However, all patients ultimately develop acquired resistance, half of which are attributed to the EGFR exon 20 T790M mutation. A landmark publication in Cancer Research in 2007 demonstrated improved drug potency and pan-human EGFR (HER) inhibition with PF00299804, a second-generation EGFR TKI. Compared with first - generation EGFR TKI, PF00299804 showed the ability to overcome T790M mutation in vitro and had the potential to improve treatment outcomes of patients with mutant EGFR-positive NSCLC. Here we review the preclinical and clinical development of PF00299804 and reflect on the lessons learned from this detouring experience.

引用

页码：3662 / 3664

页数：3

共 10 条

[1] Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial [J].

Ellis, Peter M. ;

Shepherd, Frances A. ;

Millward, Michael ;

Perrone, Francesco ;

Seymour, Lesley ;

Liu, Geoffrey ;

Sun, Sophie ;

Cho, Byoung Chul ;

Morabito, Alessandro ;

Leighl, Natasha B. ;

Stockler, Martin R. ;

Lee, Christopher W. ;

Wierzbicki, Rafal ;

Cohen, Victor ;

Blais, Normand ;

Sangha, Randeep S. ;

Favaretto, Adolfo G. ;

Kang, Jin Hyoung ;

Tsao, Ming-Sound ;

Wilson, Carolyn F. ;

Goldberg, Zelanna ;

Ding, Keyue ;

Goss, Glenwood D. ;

Bradbury, Penelope Ann .

LANCET ONCOLOGY, 2014, 15 (12) :1379-1388

[2] PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Gale, Christopher-Michael ;

Lifshits, Eugene ;

Gonzales, Andrea J. ;

Shimamura, Takeshi ;

Zhao, Feng ;

Vincent, Patrick W. ;

Naumov, George N. ;

Bradner, James E. ;

Althaus, Irene W. ;

Gandhi, Leena ;

Shapiro, Geoffrey I. ;

Nelson, James M. ;

Heymach, John V. ;

Meyerson, Matthew ;

Wong, Kwok-Kin ;

Janne, Pasi A. .

CANCER RESEARCH, 2007, 67 (24) :11924-11932

[3] Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial [J].

Jaenne, Pasi A. ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Oxnard, Geoffrey R. ;

Martins, Renato ;

Kris, Mark G. ;

Dunphy, Frank ;

Nishio, Makoto ;

O'Connell, Joseph ;

Paweletz, Cloud ;

Taylor, Ian ;

Zhang, Hui ;

Goldberg, Zelanna ;

Mok, Tony .

LANCET ONCOLOGY, 2014, 15 (13) :1433-1441

[4] Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors [J].

Jaenne, Pasi A. ;

Boss, David S. ;

Camidge, D. Ross ;

Britten, Carolyn D. ;

Engelman, Jeffrey A. ;

Garon, Edward B. ;

Guo, Feng ;

Wong, Steven ;

Liang, Jane ;

Letrent, Stephen ;

Millham, Robert ;

Taylor, Ian ;

Eckhardt, S. Gail ;

Schellens, Jan H. M. .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1131-1139

[5] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[6] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[7] Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations [J].

Mok, Tony S. ;

Cheng, Ying ;

Zhou, Xiangdong ;

Lee, Ki Hyeong ;

Nakagawa, Kazuhiko ;

Niho, Seiji ;

Lee, Min ;

Linke, Rolf ;

Rosell, Rafael ;

Corral, Jesus ;

Migliorino, Maria Rita ;

Pluzanski, Adam ;

Sbar, Eric I. ;

Wang, Tao ;

White, Jane Liang ;

Wu, Yi-Long .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2244-+

[8] Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial [J].

Ramalingam, Suresh S. ;

Jaenne, Pasi A. ;

Mok, Tony ;

O'Byrne, Kenneth ;

Boyer, Michael J. ;

Von Pawel, Joachim ;

Pluzanski, Adam ;

Shtivelband, Mikhail ;

Iglesias Docampo, Lara ;

Bennouna, Jaafar ;

Zhang, Hui ;

Liang, Jane Q. ;

Doherty, Jim P. ;

Taylor, Ian ;

Mather, Cecile B. ;

Goldberg, Zelanna ;

O'Connell, Joseph ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2014, 15 (12) :1369-1378

[9] A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib [J].

Reckamp, Karen L. ;

Giaccone, Giuseppe ;

Camidge, D. Ross ;

Gadgeel, Shirish M. ;

Khuri, Fadlo R. ;

Engelman, Jeff A. ;

Koczywas, Marianna ;

Rajan, Arun ;

Campbell, Alicyn K. ;

Gernhardt, Diana ;

Ruiz-Garcia, Ana ;

Letrent, Stephen ;

Liang, Jane ;

Taylor, Ian ;

O'Connell, Joseph P. ;

Jaenne, Pasi A. .

CANCER, 2014, 120 (08) :1145-1154

[10] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Soria, J. -C. ;

Ohe, Y. ;

Vansteenkiste, J. ;

Reungwetwattana, T. ;

Chewaskulyong, B. ;

Lee, K. H. ;

Dechaphunkul, A. ;

Imamura, F. ;

Nogami, N. ;

Kurata, T. ;

Okamoto, I. ;

Zhou, C. ;

Cho, B. C. ;

Cheng, Y. ;

Cho, E. K. ;

Voon, P. J. ;

Planchard, D. ;

Su, W. -C. ;

Gray, J. E. ;

Lee, S. -M. ;

Hodge, R. ;

Marotti, M. ;

Rukazenkov, Y. ;

Ramalingam, S. S. ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125

← 1 →